RxDoctor Payments Data

Stephanie Bissonnette, DO

Neurology · Boston, MANPI 1164867792

Payments from drug & device makers

$50,993in general payments, 2019–2025

Across 93 payments — averaging $548.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$45K
  • Neurocrine Biosciences, Inc.$4K
  • Teva Pharmaceuticals USA, Inc.$328
  • Amneal Pharmaceuticals LLC$283
  • AbbVie$186
  • MDD US Operations, LLC$183
  • plus $647 from 12 others

What the payments were for

  • Speaking & faculty fees$1324%
  • Travel & lodging$1,24038%
  • Food & beverage$1,86958%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$50,993 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$49,362
Medicare patients
270
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa16$32,880
Carbidopa-Levodopa ErCarbidopa/Levodopa130$7,724
MovantikNaloxegol Oxalate14$7,308
Carbidopa-LevodopaCarbidopa/Levodopa226$5,959
Tetrabenazine22$4,059
Rasagiline Mesylate32$2,283
Entacapone11$1,850
Pregabalin21$1,661
AmantadineAmantadine Hcl27$1,464
Rivastigmine17$1,246
Propranolol Hcl ErPropranolol Hcl41$1,194
Primidone50$926
Gabapentin77$905
Memantine Hcl22$831
Donepezil Hcl59$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$283$32,88016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →